🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Ofri Mosenzon

Alzheimer's Association of Israel

ORCID: 0000-0002-5702-7584

Also affiliated with Mental Health Association of Westchester County

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses”.

Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses

Diabetes Therapy(2021)10.1007/s13300-020-00994-9
N/A
0.968DataRank · unranked
20 citations

Matthew J. Crowley, Mette Gislum, CHRISTIN L. HERTZ, Thomas Bo Jensen, Kamlesh Khunti +3 more

Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease

Circulation Genomic and Precision Medicine(2021)10.1161/circgen.120.003006
N/A
0DataRank · unranked
14 citations

Giorgio Melloni, Yared Gurmu, Marc P. Bonaca, Frederick Kamanu, Carolina Roselli +17 more

Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition

JCI Insight(2023)10.1172/jci.insight.164296
N/A
0DataRank · unranked
55 citations

Yael Riahi, Ifat Abramovich, Ofri Mosenzon, Bella Agranovich, Liat Kadosh +10 more

Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes

Diabetes Care(2023)10.2337/dc23-0492
N/A
0DataRank · unranked
14 citations

David D. Berg, Andrea Bellavia, Jamie P. Dwyer, Ofri Mosenzon, Benjamin M. Scirica +8 more

Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses

UNC Libraries(2024)10.17615/b2w6-2e46
N/A
0DataRank · unranked
0 citations

P. Ronksley E., H L, Kamlesh Khunti, Crowley M.J, Jensen T.B +3 more